Objective: To improve opioid repsonse in patients with movementrelated pain by using opioid switching adding a burst of ketamine.
I n cancer population, breakthrough pain is a transitory flare of pain superimposed on an otherwise stable pain pattern in patients treated with opioids. The most known form of breakthrough pain is incident pain, due to movement and commonly associated with bone metastases. This type of breakthrough pain limits the functional activity of these patients and freedom of pain in motion is particularly difficult. 1 The development of this pain is rapid and no medication is needed as such a short onset to parallel this temporal pattern of pain firing. In a previous study, we used a construct based on the prevention of this event, increasing the opioid doses above those sufficient to control pain at rest. 2 This resulted in an optimal basal pain control, also allowing an acceptable level of incident pain intensity. This approach was based on experimental models in animals showing that bone metastases are associated with the development of mechanical allodynia and a reduction in pain threshold, and that the doses of morphine required to block bone cancer pain-related behaviors were consistently higher than those required to block peak inflammatory pain behaviors of comparable magnitude. [3] [4] [5] This means that similar pain intensities induced by different stimuli (cancer cells injected in bone or inflammatory stimulus), may have different sensibility to opioids. However, in the clinical setting, some patients developed adverse effects with certain intensity, requiring symptomatic treatment or decrease in opioid doses. There is also evidence for spinal dorsal horn hyperexcitability after sustained opioid exposure. 6 These aspects introduce the concept of possible differences in opioid response in the attempt to optimize opioid therapy to limit pain induced by movement in patients with bone metastases. The role of opioid switching in this special context of spinal hyperexcitation has never assessed. In contrast, ketamine has been used in states of hyperexcitation associated with neuropathic pain. 7 We present 2 case reports where opioid switching plus a burst of ketamine significantly improved pain on movement in patients with movement-related pain associated with bone metastases.
CASE REPORTS
A 52-year-old man with rectal cancer was admitted to an acute pain relief and palliative care unit for lumbar-pelvic pain, tenesmus, and irradiated leg pain. He had undergone rectal resection and colostomy, followed by radiotherapy and chemotherapy. A recent computed tomography scan demonstrated a pelvic relapse with a sacral mass invading the paravertebral tissues, and compressing the nervous sacral roots and rectum. He was receiving oxycodone 30 mg/d and oral transmucosal fentanyl citrate (OTFC) 400 mg as needed for breakthrough pain, unsuccessfully. The patient was bedridden and could not move his legs due to the rapid development of excruciating incident pain (10 out of 10 on a numerical scale 0 to 10), which limited any mobilization. Basal pain ranged from 6 out of 10 to 9 out of 10. According to local policy aimed to optimize the opioid therapy to prevent or mitigate the incident pain and increasing the physical activity, opioid titration with intravenous morphine and a continuous morphine infusion of 40 mg/d were started, providing 6 mg for breakthrough pain. In the following 24 hours, infusion rate was increased. Basal pain improved (3 out of 10) and incident pain was more tolerable (8 out of 10). The patient, however, developed drowsiness and nausea, which limited further opioid escalation. This type of response prompted to switch to an intravenous infusion of 15 mg of intravenous methadone, assisted by 3 mg as needed. Concomitantly, a ketamine infusion of 100 mg/d was planned for 2 days. Intravenous methadone was progressively increased up to 30 mg/d, taking the amounts of patient's requests for breakthrough medication into consideration. After 2 days, the patient was able to stand up and be autonomous for his daily activities. Ketamine infusion was stopped, intravenous methadone was converted to the oral route in doses of 60 mg/d, and OTFC 1200 mg given as needed, for 1 to 2 requests a day. After 2 days, when the patient was able to walk without any help or specific assistance, he was discharged home.
A 57-year-old woman with gallbladder cancer and liver metastases was admitted at the Pain Relief and Palliative Care Unit for abdominal and shoulder pain. She had previously undergone colecistectomy, different courses of chemotherapy, and had a biliary drainage. Pain was aching and exacerbating with arm movement. A magnetic nuclear resonance showed shoulder bone involvement. She was previously receiving morphine 180 mg/d for her pain. This dosage was reduced some days before admission for the occurrence of adverse effects, including vomiting and drowsiness. Basal pain was 8 out of 10 on a numerical pain scale 0 to 10, and she was unable to move her arm for minimal activity, such as eating and drinking. After a rapid morphine dose titration with 10 mg, an infusion of 60 mg/d and the same titration dose prescribed as needed were started successfully. However, in the subsequent hours the patient developed severe drowsiness and vomiting, persisting despite a decrease in infusion rate of intravenous morphine (45 mg/h), which determined in turn an increase in basal pain intensity (6 out of 10), preventing any arm movement. Intravenous morphine was substituted with intravenous methadone at an infusion rate of 12 mg/d and OTFC 600 mg as needed. Concomitantly, a ketamine infusion of 100 mg/d was planned for 2 days. The day after pain control was acceptable (3 out of 10), and cognitive disturbances and gastrointestinal symptoms disappeared. Incident pain due to movement was not excruciating (7 out of 10) and responsive to OTFC. After 2 days, ketamine infusion was stopped and intravenous methadone converted to 15 mg/d of methadone orally. The patient remained stable for the next 3 days and was discharged home with wellcontrolled basal pain, able to move the arm, and responsive to OTFC after breakthrough pain occurred with a prolonged activity.
DISCUSSION
Opioid doses may be escalated to allow a better mobility in patients with bone metastases when incident pain is so strong that movements are prevented, strongly limiting patients quality of life.
2 By increasing pain threshold, it is to prevent or render the majority of pain on movement more acceptable. The occurrence of adverse effects, however, may limit this approach. In these circumstances extra doses of opioids as needed are not useful, although occasionally preemptive doses of opioids are given for this purpose. Timing, kind of opioid, and dosing of preemptive opioids have never been clarified.
The construct of optimizing opioid doses in patients with an apparent basal pain control is based on experimental studies in animals, which have shown that bone metastases generate a unique set of neurochemical changes in the spinal cord and sensory neurons. 3 These changes are characterized by the development of a mechanical allodynia, translating in the clinical setting in an increasing pain after a potentially innocuous stimulus, such as a movement. Doses of opioids required to block bone cancer pain-related behaviors were consistently higher than those required to block peak inflammatory pain behaviors of comparable magnitude. 4, 5 This suggests that similar pain intensities induced by different stimuli (cancer cells injected in bone or inflammatory stimulus), may have different sensibility to opioids, also introducing the concept of a different response to different opioids even in this context. Of interest, neurochemical changes are similar to those observed with tolerance and opioid induced hyperalgesia, characterized by a rightward shift of opioid antinociceptive dose-response curve, 8 suggesting a possible benefit in substituting the opioid. In experimental setting, it has been demonstrated that the development of tolerance and hyperalgesic state involves the activation of excitatory glutamate receptors at the N-methyl-D-aspartate type in the central nervous system. 7 Burst ketamine, a well known N-methyl-Daspartate-antagonist agent, has been successfully used to limit or reverse opioid hyperalgesia in cancer patients. 9, 10 Opioid switching to methadone, associated with a burst of ketamine significantly improved patients' mobilization, allowing a sufficient autonomy for daily activities, such as sitting, eating, and walking, activities important for their quality of life. Although the possibility to use opioid switching to improve opioid response is well known, no data exist about this specific context, where increasing doses of opioids, tailored to improve mobilization, failed for the occurrence of adverse effects.
Data from this report suggests that optimization of basal opioid therapy, eventually forced with opioid switching and burst ketamine, should be considered in cancer patients with bone metastases presenting incident pain who probably have a hypersensitivity to innocuous stimuli, such as movement, and require a more effective opioid when the first fails at the maximum tolerated doses, due to the occurrence of adverse effects.
Given the conjectural nature of this approach, results should be interpreted with caution, and further studies should be considered, for example in animals, as such study designs are difficult to set up in a clinical context. Translational research could make important contributions to basic pain research and its application, according to a 2-way approach, one being from bedside to bench and the other from bench to bedside, integrating information and coordinating research efforts between these 2 fields.
